161 related articles for article (PubMed ID: 25501109)
1. Clinical features and outcomes of 9 patients with immunodeficiency-associated lymphoproliferative disorders treated at a single institution.
Kawano N; Ono N; Kawano S; Kuriyama T; Yoshida S; Inoue S; Yamashita K; Himeji D; Shimao Y; Marutsuka K; Oshima K; Ueda A; Kawano F
J Clin Exp Hematop; 2014; 54(3):187-96. PubMed ID: 25501109
[TBL] [Abstract][Full Text] [Related]
2. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders.
Tokuhira M; Tamaru JI; Kizaki M
J Clin Exp Hematop; 2019; 59(2):72-92. PubMed ID: 31257348
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.
Gion Y; Iwaki N; Takata K; Takeuchi M; Nishida K; Orita Y; Tachibana T; Yoshino T; Sato Y
Cancer Sci; 2017 Jun; 108(6):1271-1280. PubMed ID: 28380678
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
[TBL] [Abstract][Full Text] [Related]
5. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
[TBL] [Abstract][Full Text] [Related]
6. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder.
Pina-Oviedo S; Miranda RN; Medeiros LJ
Am J Surg Pathol; 2018 Jan; 42(1):116-129. PubMed ID: 29112013
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.
Kawano N; Ono N; Yoshida S; Kuriyama T; Yamashita K; Beppu K; Shimao Y; Marutsuka K; Ueda Y; Ueda A
J Clin Exp Hematop; 2012; 52(3):193-8. PubMed ID: 23269079
[TBL] [Abstract][Full Text] [Related]
10. Polymorphic lymphoproliferative disorders in patients with rheumatoid arthritis are associated with a better clinical outcome.
Tsukui D; Kanda H; Shinozaki-Ushiku A; Tateishi S; Takeshima Y; Nagafuchi Y; Sasaki O; Iwasaki Y; Harada H; Shibuya M; Sumitomo S; Shoda H; Kubo K; Fujio K; Nakamura F; Kurokawa M; Fukayama M; Yamamoto K
Mod Rheumatol; 2018 Jul; 28(4):621-625. PubMed ID: 29057700
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
Toyonaga H; Fukushima M; Shimeno N; Inokuma T
BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
[TBL] [Abstract][Full Text] [Related]
12. [Primary central nervous system methotrexate associated lymphoproliferative disorders in a patient with rheumatoid arthritis].
Uchida Y; Hokkoku K; Hatanaka Y; Kikuchi Y; Tashiro H; Sonoo M
Rinsho Shinkeigaku; 2018 Aug; 58(8):485-491. PubMed ID: 30068810
[TBL] [Abstract][Full Text] [Related]
13. Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorder Presenting as Primary Bone Lymphoma in a Patient with Rheumatoid Arthritis.
Ishiguro K; Hayashi T; Aoki Y; Murakami R; Ikeda H; Ishida T
Intern Med; 2016; 55(16):2259-64. PubMed ID: 27523005
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid arthritis relapse in patients with other iatrogenic immunodeficiency-associated lymphoproliferative disorders and its treatment.
Nagafuchi H; Goto Y; Suzuki S; Sakurai K; Imamura M; Suzuki T; Yamasaki Y; Shibata T; Kawahata K
Mod Rheumatol; 2021 Nov; 31(6):1087-1093. PubMed ID: 33491519
[TBL] [Abstract][Full Text] [Related]
15. Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders.
Watanabe M; Kanda J; Hishizawa M; Nishikori M; Kondo T; Yamashita K; Takaori-Kondo A
Ann Hematol; 2020 Jul; 99(7):1565-1573. PubMed ID: 32436013
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.
Gion Y; Doi M; Nishimura Y; Ikeda T; Filiz Nishimura M; Sakamoto M; Egusa Y; Nishikori A; Fujita A; Iwaki N; Nakamura N; Yoshino T; Sato Y
Cancer Med; 2022 Jan; 11(2):417-432. PubMed ID: 34842351
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous methotrexate-associated B-cell lymphoproliferative disorders other than EBV-positive mucocutaneous ulcer: clinical, pathological, and immunophenotypic features.
Satou A; Banno S; Kohno K; Takahara T; Takahashi E; Nobata H; Iwagaitsu S; Watanabe D; Hanamura I; Takami A; Ito Y; Nakamura S; Tsuzuki T
Pathology; 2021 Aug; 53(5):595-601. PubMed ID: 33618861
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.
Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A
Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893
[TBL] [Abstract][Full Text] [Related]
20. The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study.
Torii A; Oki M; Iida H; Yamada A; Kogure Y; Kitagawa C; Saka H
Pulm Pharmacol Ther; 2024 Jun; 85():102297. PubMed ID: 38467341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
